179 related articles for article (PubMed ID: 26372210)
1. CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer.
Barrón EV; Roman-Bassaure E; Sánchez-Sandoval AL; Espinosa AM; Guardado-Estrada M; Medina I; Juárez E; Alfaro A; Bermúdez M; Zamora R; García-Ruiz C; Gomora JC; Kofman S; Pérez-Armendariz EM; Berumen J
PLoS One; 2015; 10(9):e0137397. PubMed ID: 26372210
[TBL] [Abstract][Full Text] [Related]
2. Targeting CDKN3 in cervical cancer.
Berumen J; Espinosa AM; Medina I
Expert Opin Ther Targets; 2014 Oct; 18(10):1149-62. PubMed ID: 25152075
[TBL] [Abstract][Full Text] [Related]
3. CDKN3 expression is negatively associated with pathological tumor stage and CDKN3 inhibition promotes cell survival in hepatocellular carcinoma.
Dai W; Miao H; Fang S; Fang T; Chen N; Li M
Mol Med Rep; 2016 Aug; 14(2):1509-14. PubMed ID: 27314282
[TBL] [Abstract][Full Text] [Related]
4. CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer.
Zhang LP; Li WJ; Zhu YF; Huang SY; Fang SY; Shen L; Gao YL
Int J Clin Exp Pathol; 2015; 8(5):4535-44. PubMed ID: 26191143
[TBL] [Abstract][Full Text] [Related]
5. Integrated transcriptomics explored the cancer-promoting genes CDKN3 in esophageal squamous cell cancer.
Wang W; Liao K; Guo HC; Zhou S; Yu R; Liu Y; Pan Y; Pu J
J Cardiothorac Surg; 2021 May; 16(1):148. PubMed ID: 34044866
[TBL] [Abstract][Full Text] [Related]
6. Mitosis is a source of potential markers for screening and survival and therapeutic targets in cervical cancer.
Espinosa AM; Alfaro A; Roman-Basaure E; Guardado-Estrada M; Palma Í; Serralde C; Medina I; Juárez E; Bermúdez M; Márquez E; Borges-Ibáñez M; Muñoz-Cortez S; Alcántara-Vázquez A; Alonso P; Curiel-Valdez J; Kofman S; Villegas N; Berumen J
PLoS One; 2013; 8(2):e55975. PubMed ID: 23405241
[TBL] [Abstract][Full Text] [Related]
7. Cyclin-Dependent Kinase Inhibitor 3 Promotes Cancer Cell Proliferation and Tumorigenesis in Nasopharyngeal Carcinoma by Targeting p27.
Wang H; Chen H; Zhou H; Yu W; Lu Z
Oncol Res; 2017 Nov; 25(9):1431-1440. PubMed ID: 28109073
[TBL] [Abstract][Full Text] [Related]
8. CDKN3 is an independent prognostic factor and promotes ovarian carcinoma cell proliferation in ovarian cancer.
Li T; Xue H; Guo Y; Guo K
Oncol Rep; 2014 Apr; 31(4):1825-31. PubMed ID: 24573179
[TBL] [Abstract][Full Text] [Related]
9. Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer.
Cress WD; Yu P; Wu J
Int J Biochem Cell Biol; 2017 Oct; 91(Pt B):98-101. PubMed ID: 28504190
[TBL] [Abstract][Full Text] [Related]
10. Silencing cyclin-dependent kinase inhibitor 3 inhibits the migration of breast cancer cell lines.
Deng M; Wang J; Chen Y; Zhang L; Xie G; Liu Q; Zhang T; Yuan P; Liu D
Mol Med Rep; 2016 Aug; 14(2):1523-30. PubMed ID: 27314680
[TBL] [Abstract][Full Text] [Related]
11. Mechanistic studies of cyclin-dependent kinase inhibitor 3 (CDKN3) in colorectal cancer.
Yang C; Sun JJ
Asian Pac J Cancer Prev; 2015; 16(3):965-70. PubMed ID: 25735390
[TBL] [Abstract][Full Text] [Related]
12. CDKN3 expression is an independent prognostic factor and associated with advanced tumor stage in nasopharyngeal carcinoma.
Chang SL; Chen TJ; Lee YE; Lee SW; Lin LC; He HL
Int J Med Sci; 2018; 15(10):992-998. PubMed ID: 30013440
[No Abstract] [Full Text] [Related]
13. Knockdown of Cyclin-Dependent Kinase Inhibitor 3 Inhibits Proliferation and Invasion in Human Gastric Cancer Cells.
Li Y; Ji S; Fu LY; Jiang T; Wu D; Meng FD
Oncol Res; 2017 May; 25(5):721-731. PubMed ID: 27983933
[TBL] [Abstract][Full Text] [Related]
14. The role of cyclin-dependent kinase inhibitor 3 in the proliferation and migration of renal cell carcinoma.
Ni C; Guo Z; Bu H; Zhao X; Bao M; Ding L; Liang C; Tang Q; Li J
Chem Biol Interact; 2024 Jul; 397():111092. PubMed ID: 38825053
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of major CDKN3 transcripts is associated with poor survival in lung adenocarcinoma.
Fan C; Chen L; Huang Q; Shen T; Welsh EA; Teer JK; Cai J; Cress WD; Wu J
Br J Cancer; 2015 Dec; 113(12):1735-43. PubMed ID: 26554648
[TBL] [Abstract][Full Text] [Related]
16. Cyclin-dependent kinase inhibitor 3 is overexpressed in hepatocellular carcinoma and promotes tumor cell proliferation.
Xing C; Xie H; Zhou L; Zhou W; Zhang W; Ding S; Wei B; Yu X; Su R; Zheng S
Biochem Biophys Res Commun; 2012 Mar; 420(1):29-35. PubMed ID: 22390936
[TBL] [Abstract][Full Text] [Related]
17. CDKN3 regulates cisplatin resistance to colorectal cancer through TIPE1.
Li WH; Zhang L; Wu YH
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(7):3614-3623. PubMed ID: 32329836
[TBL] [Abstract][Full Text] [Related]
18. miR-202 inhibits the progression of human cervical cancer through inhibition of cyclin D1.
Yi Y; Li H; Lv Q; Wu K; Zhang W; Zhang J; Zhu D; Liu Q; Zhang W
Oncotarget; 2016 Nov; 7(44):72067-72075. PubMed ID: 27732565
[TBL] [Abstract][Full Text] [Related]
19. The tumor suppressor CDKN3 controls mitosis.
Nalepa G; Barnholtz-Sloan J; Enzor R; Dey D; He Y; Gehlhausen JR; Lehmann AS; Park SJ; Yang Y; Yang X; Chen S; Guan X; Chen Y; Renbarger J; Yang FC; Parada LF; Clapp W
J Cell Biol; 2013 Jun; 201(7):997-1012. PubMed ID: 23775190
[TBL] [Abstract][Full Text] [Related]
20. Decreased expression of lncRNA GAS5 predicts a poor prognosis in cervical cancer.
Cao S; Liu W; Li F; Zhao W; Qin C
Int J Clin Exp Pathol; 2014; 7(10):6776-83. PubMed ID: 25400758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
